Actinogen Medical Limited (ASX:ACW) has been reinstated to quotation on the Australian Securities Exchange following the release of an announcement regarding clinical trial results for the XanaMIA phase 2b/3 trial, with the suspension of trading in ACW securities lifted immediately, according to a filing issued by ASX Supervision on 19 November 2026.

Key Points

  • The suspension of trading in Actinogen Medical Limited (ASX:ACW) securities has been lifted immediately.
  • Reinstatement to quotation followed the release of an announcement regarding clinical trial results for the XanaMIA phase 2b/3 trial.
  • The notice was issued by ASX Supervision on 19 November 2026.

Reinstatement to Quotation

ASX Supervision issued a market notice on 19 November 2026 confirming the suspension of trading in Actinogen Medical Limited securities would be lifted immediately. The reinstatement followed the company's release of an announcement concerning clinical trial results for its XanaMIA phase 2b/3 trial. The filing states that the lifting of suspension was conditional upon the release of that announcement, and took effect immediately upon its publication. No further conditions or timelines for reinstatement were disclosed in the filing.

XanaMIA Phase 2b/3 Trial

The filing identifies the XanaMIA phase 2b/3 trial as the subject of the clinical trial results announcement that preceded the reinstatement of Actinogen Medical's securities to quotation. No details regarding the content, outcomes, findings, or data from the XanaMIA phase 2b/3 trial results are disclosed within this particular filing. The filing solely references the existence of a separate announcement regarding those results as the basis for the trading suspension being lifted by ASX Supervision.

ASX Supervision Notice Details

The market notice was issued by ASX Supervision and dated 19 November 2026. The document is identified under filing reference numbers included in the notice. The notice confirms that the suspension of trading in the securities of Actinogen Medical Limited, trading under the ticker ACW, was in place prior to this date and has been lifted immediately following the company's disclosure of the clinical trial results announcement. No additional regulatory requirements or conditions beyond the release of the results announcement are referenced in this filing.